Compare MDV & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | ZNTL |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.4M | 156.7M |
| IPO Year | N/A | 2020 |
| Metric | MDV | ZNTL |
|---|---|---|
| Price | $15.07 | $2.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $19.00 | $5.80 |
| AVG Volume (30 Days) | 63.3K | ★ 533.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.09% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.80 | $1.01 |
| 52 Week High | $17.15 | $3.95 |
| Indicator | MDV | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 54.34 |
| Support Level | $14.08 | $1.31 |
| Resistance Level | $15.56 | $2.69 |
| Average True Range (ATR) | 0.40 | 0.21 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 96.95 | 86.23 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.